drugset / Trial / NCT05308212
Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra
RandomizedParallel-groupDouble-blindPrevention
Summary
Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in volunteers aged 60 years and above.
Timeline
- Start
- 2021-03-04
- Primary completion
- 2021-07-30
- Completion
- 2021-09-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flu-M Tetra | Vaccine | 0.5 ml | Intramuscular |
| Comparator | Ultrix | Vaccine | 0.5 ml | Intramuscular |